Cannonau Corp. (CNNC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannonau Corp. (CNNC) trades at $0.00 with AI Score 36/100 (Grade D). Cannonau Corp. focuses on developing cannabidiol-based products. The company, formerly Pacific Blue Energy Corp. Market cap: $72,413, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CNNC: CNNC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNNC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNNC: 1/1 perspectives are bearish.
How is this calculated? →Cannonau Corp. (CNNC) Healthcare & Pipeline Overview
Cannonau Corp., a small-cap company in the specialty and generic drug manufacturing sector, focuses on developing cannabidiol-based products. Formerly Pacific Blue Energy Corp., the company operates from Skaneateles, New York, and faces competition in the rapidly evolving CBD market.
What Is the Investment Thesis for CNNC?
Cannonau Corp. presents a speculative investment opportunity within the high-growth CBD market. The company's small size and limited operating history introduce significant risks. Key value drivers include successful product development and market penetration within the competitive CBD landscape. The company's ability to secure funding and navigate regulatory hurdles will be critical for long-term viability. With a market capitalization of 72K and a P/E ratio of 0.0, traditional valuation metrics offer limited insight. The company's beta of 1.52 indicates higher volatility compared to the broader market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company in a rapidly evolving industry.
Based on FMP financials and quantitative analysis
CNNC Key Highlights
- Cannonau Corp. focuses on the development of cannabidiol (CBD) based products, tapping into the growing market for alternative health solutions.
- The company was formerly known as Pacific Blue Energy Corp., indicating a strategic shift in business focus towards the healthcare sector in August 2019.
- Cannonau Corp. is based in Skaneateles, New York, operating with a small team of 4 employees.
- The company's market capitalization is $0.00B, reflecting its early stage and potential for growth or risk.
- Cannonau Corp. trades on the OTC market, which typically involves higher risk and lower liquidity compared to major exchanges.
Who Are CNNC's Competitors?
CNNC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNNC's Key Strengths?
- Focus on the growing CBD market.
- Potential for innovative product development.
- Strategic shift towards healthcare applications.
- Small size allows for agility and adaptability.
What Are CNNC's Weaknesses?
- Limited financial resources.
- Small team and limited operational capacity.
- Lack of established brand recognition.
- Dependence on a single product category (CBD).
What Could Drive CNNC Stock Higher?
- Potential regulatory changes in key markets could create new opportunities for CBD products.
- Increasing consumer awareness and acceptance of CBD may drive demand for Cannonau Corp.'s products.
- Successful development and launch of new CBD formulations could boost revenue and market share.
- Strategic partnerships with established healthcare companies could expand distribution channels.
- Positive clinical trial results for CBD applications could enhance product credibility.
What Are the Key Risks for CNNC?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger companies in the CBD market.
- Evolving regulatory landscape could restrict the sale or marketing of CBD products.
- Negative publicity or safety concerns related to CBD could damage consumer confidence.
- Fluctuations in the price of CBD raw materials could impact profitability.
- Limited financial resources may hinder Cannonau Corp.'s ability to compete effectively.
What Are the Growth Opportunities for CNNC?
- Expansion of Product Line: Cannonau Corp. can expand its product line beyond basic CBD offerings to include specialized formulations targeting specific health conditions. The market for condition-specific CBD products is growing rapidly, with a potential market size of $5 billion by 2028. This expansion requires investment in research and development, but could significantly increase revenue and market share. The timeline for launching new products is estimated at 12-18 months, contingent on regulatory approvals and successful clinical trials.
- Strategic Partnerships: Forming strategic partnerships with established healthcare companies or retailers can provide Cannonau Corp. with access to wider distribution channels and increased brand recognition. The market for CBD products through established retail channels is projected to reach $8 billion by 2027. Partnering with a major retailer could provide immediate access to this market. The timeline for establishing such partnerships is estimated at 6-12 months, depending on negotiation and due diligence processes.
- Online Sales and Marketing: Developing a strong online presence and implementing effective digital marketing strategies can help Cannonau Corp. reach a broader customer base and build brand awareness. The online CBD market is expected to reach $6 billion by 2026. Investing in search engine optimization (SEO) and social media marketing can drive traffic to the company's website and increase online sales. The timeline for implementing these strategies is ongoing, with continuous optimization and adaptation required to maintain a competitive edge.
- Geographic Expansion: Expanding operations beyond the current base in Skaneateles, New York, to new geographic markets can unlock significant growth opportunities. The global CBD market is projected to reach $47 billion by 2028. Targeting specific regions with favorable regulatory environments and high consumer demand can drive revenue growth. The timeline for geographic expansion is estimated at 12-24 months, depending on regulatory approvals and market entry strategies.
- Research and Development: Investing in research and development to develop innovative CBD formulations and delivery methods can provide Cannonau Corp. with a competitive advantage. The market for novel CBD formulations is growing rapidly, with a potential market size of $3 billion by 2027. Developing patented formulations can protect the company's intellectual property and create a barrier to entry for competitors. The timeline for developing and patenting new formulations is estimated at 24-36 months, requiring significant investment in research and clinical trials.
What Opportunities Does CNNC Have?
- Expansion into new CBD product categories.
- Strategic partnerships with established healthcare companies.
- Increased consumer awareness of CBD benefits.
- Favorable regulatory changes in key markets.
What Threats Does CNNC Face?
- Intense competition from larger companies.
- Evolving regulatory landscape for CBD products.
- Potential negative publicity or safety concerns related to CBD.
- Fluctuations in the price of CBD raw materials.
What Are CNNC's Competitive Advantages?
- Proprietary CBD formulations (if any).
- Brand recognition and customer loyalty (if established).
- Strategic partnerships with distributors or retailers.
- Intellectual property protection through patents (if any).
What Does CNNC Do?
Cannonau Corp., established in 2007 and formerly known as Pacific Blue Energy Corp., transitioned its focus to the development of cannabidiol (CBD) based products in August 2019. Headquartered in Skaneateles, New York, the company operates within the specialty and generic drug manufacturing industry, specifically targeting the burgeoning CBD market. Cannonau Corp. aims to capitalize on the increasing consumer interest in CBD for various health and wellness applications. As a relatively small player with only 4 employees, Cannonau Corp. faces the challenge of competing with larger, more established companies in the pharmaceutical and wellness sectors. The company's success hinges on its ability to innovate, develop effective CBD products, and establish a strong market presence in a competitive landscape. The company's evolution from Pacific Blue Energy Corp. signals a strategic shift towards the healthcare sector, specifically focusing on the potential of cannabidiol-based therapies and products.
What Products and Services Does CNNC Offer?
- Develop cannabidiol (CBD) based products.
- Focus on the healthcare sector with CBD applications.
- Operate as a specialty and generic drug manufacturer.
- Engage in research and development for new CBD formulations.
- Market and distribute CBD products to consumers.
- Explore potential therapeutic applications of CBD.
How Does CNNC Make Money?
- Develop and formulate CBD-based products.
- Market and sell these products directly to consumers or through retail channels.
- Generate revenue through product sales.
- Potentially license or partner for distribution and manufacturing.
What Industry Does CNNC Operate In?
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry, specifically targeting the cannabidiol (CBD) market. This market has experienced rapid growth in recent years, driven by increasing consumer awareness of CBD's potential health benefits. However, the industry is also characterized by intense competition and evolving regulatory landscapes. Companies like ACUR, AZFL, CBDX, FIORF, and FLHLF also compete in this space. Cannonau Corp.'s success depends on its ability to differentiate its products and navigate the complex regulatory environment.
Who Are CNNC's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Consumers interested in the potential therapeutic benefits of CBD.
- Retailers and distributors of health and wellness products.
- Potential partnerships with healthcare providers.
Company Profile
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Skaneateles, US. The company is led by CEO Markwin Maring. CNNC has traded publicly since 2010.
F-Score 2/9Financial Health
Cannonau Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
P/E 0.0Key Financial Metrics
CNNC trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
CNNC Valuation & Market Position
With a 72K market cap, Cannonau Corp. sits in the micro-cap segment of the market. Relative to its peer group, CNNC's quantitative score of 36/100 is below the peer average of 66/100.
CNNC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on the growing CBD market.
- Potential for innovative product development.
- Strategic shift towards healthcare applications.
- Small size allows for agility and adaptability.
Bear Case
- Limited financial resources.
- Small team and limited operational capacity.
- Lack of established brand recognition.
- Dependence on a single product category (CBD).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CNNC Latest News
No recent news available for CNNC.
CNNC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNNC.
Price Targets
Wall Street price target analysis for CNNC.
CNNC MoonshotScore
What does this score mean?
The MoonshotScore rates CNNC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Markwin Maring
CEO
Markwin Maring serves as the CEO of Cannonau Corp., leading a small team of 4 employees. Information regarding his detailed career history, educational background, and previous roles is not available. As the CEO, he is responsible for the overall strategic direction and operational management of the company, guiding its focus on developing cannabidiol-based products. His leadership is crucial for navigating the competitive CBD market and achieving the company's growth objectives.
Track Record: Due to limited information, Markwin Maring's specific achievements, strategic decisions, and company milestones under his leadership at Cannonau Corp. are currently unknown. Evaluating his track record requires further data on the company's performance and strategic initiatives since he assumed the role of CEO.
CNNC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannonau Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in these companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2007.
- Company has a website and contact information.
- Company has a stated business focus (CBD products).
- Company has a CEO and a small team of employees.
- Company has undergone a name change to reflect its current focus.
CNNC Healthcare Stock FAQ
What does Cannonau Corp. do?
Cannonau Corp. is a small company focused on developing and potentially marketing cannabidiol (CBD) based products. Operating in the specialty and generic drug manufacturing industry, the company aims to capitalize on the growing consumer interest in CBD for various health and wellness applications. Cannonau Corp. faces the challenge of competing with larger, more established companies in the pharmaceutical and wellness sectors. Its success depends on its ability to innovate, develop effective CBD products, and establish a strong market presence.
What do analysts say about CNNC stock?
There is currently no available analyst coverage for Cannonau Corp. (CNNC). As a small, OTC-listed company with a limited operating history, CNNC does not attract coverage from major financial analysts. Investors should rely on their own independent research and due diligence to assess the company's potential and risks. The lack of analyst coverage reflects the speculative nature of the investment and the limited information available to the public.
What are the main risks for CNNC?
Cannonau Corp. faces several significant risks, including intense competition in the rapidly evolving CBD market, the evolving and uncertain regulatory landscape for CBD products, and the company's limited financial resources. Negative publicity or safety concerns related to CBD could also negatively impact consumer demand. As an OTC-listed company, CNNC is subject to less stringent regulatory oversight and faces higher risks of fraud or mismanagement. Investors should carefully consider these risks before investing in CNNC.
What are the key factors to evaluate for CNNC?
Cannonau Corp. (CNNC) holds an AI score of 36/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CNNC data refresh on this page?
CNNC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CNNC's recent stock price performance?
Cannonau Corp. (CNNC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the growing CBD market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNNC overvalued or undervalued right now?
Cannonau Corp. (CNNC) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CNNC?
Before investing in Cannonau Corp. (CNNC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Cannonau Corp. due to its OTC listing and small size.
- Financial data is limited, making it difficult to assess the company's true value and potential.
- AI analysis is pending, which may provide additional insights in the future.